Drugs in Dev. Nephrology
Phase III
Germany 
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kerendia (finerenone) is a non-steroidal mineralocorticoid receptor antagonist and was approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization ...
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kerendia/Firialta (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block harmful effects of MR overactivation. It has been granted marketing authorization for expanded indication in China for chronic...
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block harmful effects of MR overactivation. It is being evaluated for the treatment of chronic kidney disease and type 2 diabetes.
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Jardiance (empagliflozin) is an inhibitor of the sodium-glucose co-transporter 2 (SGLT2), which leads in lowering renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Product Name : Jardiance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JARDIANCE (empagliflozin) is a prescription medicine used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of your body.
Product Name : Jardiance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone,Empagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The submission is based on positive data from the FIGARO-DKD study, which demonstrated that Kerendia (finerenone) significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D.
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Finerenone,Empagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Jardiance (empagliflozin), is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.
Product Name : Jardiance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA was based on Phase III FIDELIO-DKD trial data. Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor antagonist that showed renal and cardiovascular benefits in patients with CKD and T2D in the Phase I...
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Finerenone significantly reduced the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care.
Product Name : Kerendia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Finerenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA grants Fast Track designation to Jardiance®
Details : The EMPA-KIDNEY clinical study is evaluating Jardiance for the progression of kidney disease and the occurrence of cardiovascular death in adults with established CKD with and without diabetes.
Product Name : Jardiance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Empagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
